Potential for cardiovascular benefits of resmetirom based on LDL-cholesterol and lipoprotein(a) lowering consistent across statin subgroups, a secondary analysis of the MAESTRO-NASH phase 3 clinical trial
- DOI
- 10.1016/j.jacl.2026.10.004
- Published
- 2026-10
- Container
- Journal of Clinical Lipidology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.jacl.2026.10.004,
title = {Potential for cardiovascular benefits of resmetirom based on LDL-cholesterol and lipoprotein(a) lowering consistent across statin subgroups, a secondary analysis of the MAESTRO-NASH phase 3 clinical trial},
author = {Meena B. Bansal and Rebecca Taub and Dominic Labriola and David Soergel and Yestle Kim and Naim Alkhouri and Mazen Noureddin and Seth Baum and Rohit Loomba},
year = {2026},
journal = {Journal of Clinical Lipidology},
doi = {10.1016/j.jacl.2026.10.004},
url = {https://doi.org/10.1016/j.jacl.2026.10.004}
}RIS
TY - JOUR TI - Potential for cardiovascular benefits of resmetirom based on LDL-cholesterol and lipoprotein(a) lowering consistent across statin subgroups, a secondary analysis of the MAESTRO-NASH phase 3 clinical trial AU - Meena B. Bansal AU - Rebecca Taub AU - Dominic Labriola AU - David Soergel AU - Yestle Kim AU - Naim Alkhouri AU - Mazen Noureddin AU - Seth Baum AU - Rohit Loomba PY - 2026 JO - Journal of Clinical Lipidology DO - 10.1016/j.jacl.2026.10.004 UR - https://doi.org/10.1016/j.jacl.2026.10.004 ER -
APA
Bansal, M. B., Taub, R., Labriola, D., Soergel, D., Kim, Y., Alkhouri, N., Noureddin, M., Baum, S., & Loomba, R. (2026). Potential for cardiovascular benefits of resmetirom based on LDL-cholesterol and lipoprotein(a) lowering consistent across statin subgroups, a secondary analysis of the MAESTRO-NASH phase 3 clinical trial. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2026.10.004
Source records
- crossref · retrieved 2026-11-08T06:10:03.393Z